Market revenue in 2021 | USD 48.6 million |
Market revenue in 2032 | USD 190.5 million |
Growth rate | 13.2% (CAGR from 2021 to 2032) |
Largest segment | Monoclonal antibodies |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 46.09% in 2021. Horizon Databook has segmented the Canada myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
The growth of Canada myasthenia gravis treatment market can be attributed to high healthcare expenditure and favorable reimbursement policies in the country, leading to higher access to innovative diagnosis and treatment therapies.
For instance, Immunovant, a U.S.-based company, is expected to announce data from its Phase 2a ASCEND MG clinical trial study, which is inspecting tolerability and safety of IMVT1401 in MG patients. The company is still recruiting participants at multiple sites in the U.S. & Canada and is expected to enroll 21 MG patients.
Moreover, rising public-private initiatives and growing investments are among factors likely to drive the market. The Myasthenia Gravis Society of Canada is among organizations providing dedicated services to improve the quality of life and deliver sophisticated medical care to MG patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Canada myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account